Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen

IV Insulin has been defined as a top-rated high-alert medication by the Institute for Safe Medication Practices, and yet options to improve the safety of these infusions have been limited until recently.  Dr. Kevin Hansen will discuss his experience using Myxredlin, a ready-to-administer insulin infusion product that has changed how many organizations manage these high-risk infusions in the US.  He will also introduce some of the concepts for consideration when organizations are exploring the introduction of ready-to-administer products including patient safety, pharmaco-economics, drug stability, human resource management, and workflows. Link to discussed publication:  https://www.pppmag.com/article/2655